Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

OrthoTrophix to present TPX-100 data at OARSI
04-18-2018
by DDNews Staff  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

OAKLAND, Calif.—OrthoTrophix, Inc., a privately held biopharmaceutical company, has announced that the company plans to report long-term clinical benefits in mild to severe knee osteoarthritis (OA) patients who were treated with TPX-100 at the 2018 OARSI annual meeting, held this year in Liverpool, U.K., from April 26 - 29.
 
OrthoTrophix previously presented the results of a Phase 2 clinical study in which the company’s OA drug candidate, TPX-100 improved knee function and physical quality of life at 6 and 12 months after treatment, compared with placebo. A follow-on protocol, TPX-100-4, assessed the same patient reported outcomes in subjects who participated in TPX-100-1.
 
The average time from the initial TPX-100 treatment was 30 months, with a range of 28 - 35 months. Exclusion criteria included knee surgery or investigational drugs for OA in the interim between TPX-100-1 and TPX-100-4. Of the 93 subjects in TPX-100-1, 53 enrolled in TPX-100-4. Topline results of this follow-on study will be included in the poster session of the 2018 OARSI annual meeting under the abstract entitled “TPX-100 Leads To Marked, Sustained Improvements In Subjects With Knee Osteoarthrits.”
 
The company’s Chief Medical Officer, Dawn McGuire, M.D., FAAN said, “The long-term follow-on study enrolled over half the TPX-100-1 subjects, despite being an observational study only. The sustained improvement in knee function for more than two years in knees injected with TPX-100 confirms our confidence in TPX-100 as a drug with the potential to modify the disease of knee osteoarthritis as patients actually experience it.”
 
Code: E04161801

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.